Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Clinical trial NCT03586024 · WITHDRAWN
Trial details
- NCT number
- NCT03586024
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-12
- Primary completion
- 2020-08-19
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.